Ternary Therapeutics

Ternary Tx

Ternary Therapeutics develops an artificial intelligence platform to design molecular glue drugs for pharmaceutical companies targeting previously undruggable proteins linked to inflammatory diseases.

Molecular Glue Labs

This company develops artificial intelligence software and infrastructure to design small-molecule drugs that reprogram protein networks to treat previously untreatable diseases.

TRIANA Biomedicines

This company develops molecular glue therapeutics for patients with cancer and other diseases using a discovery platform and computational tools.

Ten63 Therapeutics

This company develops small-molecule drugs for pharmaceutical partners and patients using a generative artificial intelligence and physics-based chemistry platform to treat undruggable protein targets.

UbiquiTx

This company develops a programmable protein modulation platform using artificial intelligence to create targeted therapies for pharmaceutical businesses and patients with complex diseases.

Aizen Therapeutics

This company develops oral peptide therapeutics for patients with chronic immune disorders using an artificial intelligence platform for molecular design.

Celeris Therapeutics

The company develops artificial intelligence software to design and discover protein degrader drugs for pharmaceutical and biotechnology organisations.

Serna Bio

This company develops an AI-native platform to discover small molecule drugs targeting RNA for pharmaceutical partners treating respiratory and other complex diseases.